Aveta Achille, Napodano Giorgio, Spena Gianluca, Contieri Roberto, Perdonà Sisto, Pinchera Biagio, Pandolfo Savio Domenico
Department of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80131 Naples, Italy.
Department of Urology, ASL NA1 Centro Ospedale del Mare, 80147 Naples, Italy.
Infez Med. 2025 Jun 1;33(2):221-225. doi: 10.53854/liim-3302-8. eCollection 2025.
is a rare Gram-negative bacterium that has been infrequently associated with human infections. It is a non-encapsulated, facultative anaerobic organism that grows well in nonselective laboratory media and exhibits variable resistance patterns. Although has been identified as a pathogen since 2006, reports of its clinical significance remain scarce, particularly in Europe. Here, we present the case of a 93-year-old male from Southern Italy, with multiple comorbidities and a history of urinary catheterization, who developed a urinary tract infection (UTI) caused by . The patient was successfully treated with ciprofloxacin and fosfomycin, achieving clinical and microbiological healing. This report examines the substantial challenges associated with rare pathogens in clinical practice, focusing on the critical need for prompt and precise identification alongside tailored treatment strategies. Additionally, it highlights the pathogen's alarming multidrug resistance capabilities, underscoring the urgent need for robust antimicrobial stewardship programs and comprehensive research into its epidemiological behavior and resistance mechanisms. Incorporating rare pathogens into differential diagnoses, particularly for elderly patients with recurrent UTIs, could improve patient outcomes significantly. Finally, these findings expand the limited existing data on infections, providing valuable insights into more precise diagnostic methodologies and tailored therapeutic approaches.
是一种罕见的革兰氏阴性菌,很少与人类感染相关。它是一种无荚膜的兼性厌氧菌,在非选择性实验室培养基中生长良好,且表现出可变的耐药模式。尽管自2006年以来已被确认为病原体,但其临床意义的报道仍然很少,尤其是在欧洲。在此,我们报告一例来自意大利南部的93岁男性病例,该患者有多种合并症且有导尿史,他发生了由 引起的尿路感染(UTI)。患者接受环丙沙星和磷霉素治疗成功,实现了临床和微生物学治愈。本报告探讨了临床实践中与罕见病原体相关的重大挑战,重点关注及时准确识别以及量身定制治疗策略的迫切需求。此外,它突出了该病原体令人担忧的多重耐药能力,强调了强有力的抗菌药物管理计划以及对其流行病学行为和耐药机制进行全面研究的迫切需求。将罕见病原体纳入鉴别诊断,特别是对于复发性UTI的老年患者,可显著改善患者预后。最后,这些发现扩展了关于 感染的有限现有数据,为更精确的诊断方法和量身定制的治疗方法提供了有价值的见解。